Abstract
We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.
Publication types
- Research Support, Non-U.S. Gov't
MeSH terms
- Antibodies, Monoclonal / immunology*
- Antibodies, Monoclonal / pharmacology
- Antibodies, Viral / immunology*
- Antibodies, Viral / pharmacology
- Coronaviridae / drug effects
- Coronaviridae / genetics
- Coronaviridae / physiology*
- Coronaviridae Infections / drug therapy
- Coronaviridae Infections / enzymology*
- Coronaviridae Infections / immunology
- Coronaviridae Infections / virology*
- Dipeptidyl Peptidase 4 / chemistry
- Dipeptidyl Peptidase 4 / genetics
- Dipeptidyl Peptidase 4 / immunology*
- Epitope Mapping
- Humans
- Protein Binding
- Protein Structure, Tertiary
- Spike Glycoprotein, Coronavirus / genetics
- Spike Glycoprotein, Coronavirus / metabolism
- Virus Internalization / drug effects
Substances
- Antibodies, Monoclonal
- Antibodies, Viral
- Spike Glycoprotein, Coronavirus
- Dipeptidyl Peptidase 4